Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit View Full Press Release Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)